Search

Background Oral anticoagulation (OAC) therapy prevents morbidity and mortality in nonvalvular atrial fibrillation; whether location of diagnosis influences OAC uptake or adherence is unknown. Methods and Results Retrospective cohort study (2008–2019), identifying adults with incident nonvalvular atrial fibrillation across health care settings (emergency department, hospital, outpatient) at high risk of stroke. OAC uptake and adherence via proportion of days covered for direct OACs and time in therapeutic range for warfarin were measured. Proportion of days covered was categorized as low (0–39%), intermediate (40–79%), and high (80–100%). Warfarin control was defined as time in therapeutic range ≥65%. All‐cause mortality was examined at a 3‐year landmark. Among 75 389 patients with nonvalvular atrial fibrillation (47.0% women, mean 77.4 years), 19.7% were diagnosed in the emergency department, 59.1% in the hospital, and 21.2% in the outpatient setting. Ninety‐day OAC uptake was 51.6% in the emergency department, 50.9% in the hospital, and 67.9% in the outpatient setting ( P P values for trend Conclusions Locale of nonvalvular atrial fibrillation diagnosis is associated with varying OAC uptake and adherence. Interventions specific to health care settings are needed to improve stroke prevention.

Introduction: Heart failure and mildly reduced ejection fraction (HFmrEF) is associated with a favourable prognosis compared heart failure with reduced EF. However, HFmrEF may be a transitory state and serial imaging might clarify if these patients demonstrate an increasing, decreasing or stable EF. Hypothesis: LVEF trajectory can identify sub-groups of patients with HFmrEF with different prognosis. Materials and Methods: Patients with a diagnosis of HF and at least two echocardiograms performed ≥6 months apart were included if the LVEF measured 40-49% on the second study. They were classified based on change from their first echocardiogram as: a) HFmrEF-Incr if LVEF had increased ≥ 10% (n=450), b) HFmrEF-Dec if LVEF had decreased ≥10% (n=512), or c) HFmrEF-stable if they did not meet the other criteria (n=389). The primary outcome was a composite of all-cause mortality or cardiovascular hospitalization (ACM/CVH). Associations with time to first event were assessed with multivariable Cox analyses adjusted for age, medical history, and medications. Results: In total, 1351 patients with HFmrEF were included (median age 74, 35.8% women). During a median follow-up of 15.3 months, ACM/CVH occurred in 811 patients (324 ACM, 487 CVH). HFmrEF-Incr was associated with a lower incidence of ACM/CVH compared to patients with HFmrEF-Stable (adjusted HR 0.72, 95% CI 0.59 - 0.87, p Conclusions: Patients with HFmrEF and positive trajectory of LVEF were less likely to experience adverse outcomes, while those with a negative LVEF trajectory demonstrated a trend to higher risk. Categories based on LVEF trajectory provide clinically meaningful information and may help physicians make decisions regarding the need to pursue more aggressive medical therapy and surveillance.